Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

• Filgotinib (Drug), also known as Jyseleca: Tablets are administered in accordance with the product label

Primary outcomes

• Treatment persistence rates [Up to 24 months]: To evaluate the treatment persistence rate at 24 months, defined as the rate of patients continuing to receive filgotinib 24 months from treatment initiation.

Secondary outcomes

• patients' assessment of pain, Visual Analogue Scale (Pain VAS) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• patients' assessment of fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F score) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• patients' assessment of Work Productivity and Activity Impairment: Rheumatoid Arthritis (WPAI-RA) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• medication adherence, compliance questionnaire rheumatology 19 (CQR19) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• medication adherence, compliance questionnaire rheumatology 5 (CQR5) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• Number of adverse events and serious adverse events [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]
• patients' assessment of Rheumatoid Arthritis Impact of Disease (RAID) [Up to 24 months; it will be evaluated as exploratory objectives in the optional 24-months extension period; i.e. at approximately 30, 36, 42, and 48 months.]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.
* Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).

Exclusion Criteria:

\- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.

• Results publication: Burmester GR, Galloway J, Bevers K, Avouac J, Romero-Yuste S, Caporali RF, Betteridge N, Van der Donckt C, Debray TPA, Tandjaoui Bouzid O, Verschueren P. Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies. Rheumatol Ther. 2026 Jul 31. doi: 10.1007/s40744-026-00874-x. Online ahead of print. PMID 42536126

• Alfasigma Study Director, Study director, Alfasigma S.p.A.